Fig. 3From: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Response rates at week 4, week 8, and week 12 in the global patients’ population (ALL), patients with high-frequency episodic migraine (HFEM), and chronic migraine (CM)Back to article page